Contact SCGE




Clinical Trial Report

Gene Therapy Trial Report

Summary

Safety and Efficacy Study of Parkinson's Disease Gene Therapy Drug (BBM-P002)

NCTID NCT05822739 (View at clinicaltrials.gov)
Description
Development Status Active
Indication Parkinson's Disease
Disease Ontology Term DOID:14330
Compound Name BBM-P002
Compound Alias BBM003
Sponsor Xiangya Hospital of Central South University
Funder Type Other
Recruitment Status
Not yet recruiting
Enrollment Count 6
Results Posted Not Available

Therapy Information

Target Gene/Variant Undisclosed
Therapy Type Undisclosed
Therapy Route In-vivo
Mechanism of Action Undisclosed
Route of Administration Intraparenchymal
Drug Product Type Viral vector
Target Tissue/Cell
Delivery System Viral transduction
Vector Type AAV
Editor Type
Dose 1 Undisclosed
Dose 2
Dose 3
Dose 4
Dose 5

Study Record Dates

Current Stage Early phase1
Submit Date 2023-03-01
Completion Date 2028-12-30
Last Update 2023-04-21

Participation Criteria

Eligible Age 40 Years - 70 Years
Standard Ages Adult, Older adult
Sexes Eligible for Study ALL

Locations

No.of Trial Sites 1
Locations China

Regulatory Information

Has US IND False
FDA Designations
Recent Updates

Resources/Links

Resources/Links

No External Links Available.